Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The speed of sequencing: Rapid molecular testing in acute myeloid leukaemia.

Created on 26 Oct 2026

Authors

Alexa J Siddon, Amer M Zeidan

Published in

British journal of haematology. Oct 25, 2026. Epub Oct 25, 2026.

Abstract

Rapid molecular testing has become increasingly important in acute myeloid leukaemia (AML), where timely identification of disease defining, prognostic and actionable genetic abnormalities directly influence early clinical management. Castellet et al. demonstrate that a centralized rapid molecular screening programme for newly diagnosed AML patients has benefit in reliably identifying favourable-risk patients and potentially actionable therapeutic targets. They show that rapid molecular testing is complementary, although it should not replace comprehensive next-generation sequencing (NGS) and cytogenetic analysis-balancing curation of important genes and sequencing strategies. Commentary on: Helena Castellet, Rapid molecular screening of adult AML: Experience from the Spanish Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplásicas (CETLAM) cooperative group. Br J Haematol 2026 (Online ahead of print). doi: 10.1111/bjh.70865.

PMID:
42928639
Bibliographic data and abstract were imported from PubMed on 26 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement